"De Bono said VIR-5500 was an engineered antibody that brought together the body's killer T-cells with tumour cells trying to evade them. This type of drug, called a T-cell engager, allowed the killer cells to wipe out the tumour ones. The special feature of VIR-5500, De Bono added, was that it was designed to only become activated within the tumour."
"We believe that such treatments may in the long term lead to cures, said Prof Johann de Bono of the Institute of Cancer Research and the Royal Marsden NHS foundation trust, who led the work. This not only minimised side-effects an important consideration as other T-cell engagers have been found to trigger severe inflammatory responses in patients with prostate cancer but allowed the drug to linger in the bloodstream, meaning fewer doses may be needed."
"Under the phase one clinical trial, funded by Vir Biotechnology, 58 men with advanced prostate cancer, and who had stopped responding to other treatments, were given VIR-5500. The researchers found the majority of patients 88% experienced only very mild side-effects."
Prostate cancer is the most common cancer among men worldwide, with 1.5 million diagnoses annually. A new immunotherapy drug called VIR-5500 shows promise in early clinical trials for advanced prostate cancer. The drug is a T-cell engager that brings together the body's killer T-cells with tumor cells, allowing immune cells to destroy cancer cells. VIR-5500 is uniquely designed to activate only within tumors, minimizing side effects and allowing it to remain in the bloodstream longer, potentially requiring fewer doses. In a phase one trial of 58 men with advanced prostate cancer who had failed other treatments, 88% experienced only mild side effects, with researchers observing improvements in prostate-specific antigen levels.
Read at www.theguardian.com
Unable to calculate read time
Collection
[
|
...
]